Delivery Order SPE2DX22D0010-SPE2D826FBR06
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Amphetamine Mix (Adderall) extended-release capsules, 20mg, with a ceiling value of $2,292.80. This firm fixed-price delivery order, with an ultimate completion date of December 10, 2025, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $4,332.85 by the Medical Supply Chain, a defense-focused federal agency, on October 24, 2025, with an ultimate completion date of October 27, 2025. The contract covers the supply of Amphetamine Mix (Adderall) Extended Release Capsules 20mg, a controlled pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. The award is a firm fixed price delivery order with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Adderall XR 20 mg capsules (100-count units) with a ceiling value of $1,457.08. This non-set-aside, firm fixed-price delivery order is scheduled for completion by December 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value pharmaceutical procurement supporting federal medical...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a $4,061.26 delivery order to AmerisourceBergen Drug Corp for Adderall tablets 20mg, with a completion date of December 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $7,596.12 to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Adderall 20 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Adderall 30mg tablets (100-count packages) under a firm fixed-price contract valued at $1,225.66. The contract, which is a non-set-aside competitive award, calls for ultimate completion by November 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,624.32 for Adderall XR 10 mg capsules (100-count units) on December 8, 2025, with an ultimate completion date of December 9, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Adderall XR 30 mg capsules (100-count units) with a ceiling value of $1,245.60. This firm fixed-price delivery order, with an ultimate completion date of December 4, 2025, represents a non-competitive set-aside award and is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Adderall XR 30 mg capsules (100-count units) with a ceiling value of $1,059.74. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The ultimate completion date for this delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Adderall XR capsules in 30mg dosage with a ceiling value of $1,089.44. This firm fixed-price delivery order, which is scheduled for completion by October 22, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D826FBR06Delivery Order
The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Amphetamine Mix (Adderall) Extended Release Capsules, 5 milligrams, with a contract ceiling value of $4,076.90. The award was made on December 10, 2025, under a firm fixed price delivery order with an ultimate completion date of December 11, 2025. This non-competitive, non-set-aside contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor to the federal government, with performance occurring at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The parent IDC enables AmerisourceBergen to fulfill a broad range of pharmaceutical and medical supply requirements across military healthcare systems worldwide. The present award for controlled-substance medication reflects the company's established capacity to deliver specialized pharmaceutical products supporting the Defense Health Agency and other federal healthcare programs, consistent with the company's extensive portfolio of federal medical procurement contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 12/9/25 |